Daina Graybosch's Stock Ratings

Leerink Partners Analyst

Daina Graybosch is an analyst at Leerink Partners. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 06/11/2024

Overall Average Return

-9.60%

Smart Score

46.3%

Overall Average Return Percentile

21st

Number of Ratings

56
Buy NowGet Alert
05/15/2024BOLTBuy Now
Bolt Biotherapeutics
$0.7533.87%$3 → $1DowngradeOutperform → Market PerformGet Alert
01/31/2024TSVTBuy Now
2seventy bio
$3.93358.35%$5 → $18UpgradeMarket Perform → OutperformGet Alert
10/30/2023TSVTBuy Now
2seventy bio
$3.93DowngradeOutperform → Market PerformGet Alert
05/12/2023BOLTBuy Now
Bolt Biotherapeutics
$0.75435.48% → $4UpgradeMarket Perform → OutperformGet Alert
03/30/2023ACLXBuy Now
Arcellx
$54.13-27.95%$35 → $39MaintainsOutperformGet Alert
02/24/2023NKTRBuy Now
Nektar Therapeutics
$1.25139.04%$5 → $3MaintainsMarket PerformGet Alert
02/03/2023MRKBuy Now
Merck & Co
$130.93-6.82%$120 → $122MaintainsOutperformGet Alert
01/23/2023MRKBuy Now
Merck & Co
$130.93-8.35%$112 → $120MaintainsOutperformGet Alert
01/10/2023TSVTBuy Now
2seventy bio
$3.93765.78%$41 → $34MaintainsOutperformGet Alert
01/06/2023IPSCBuy Now
Century Therapeutics
$3.43308.16%$20 → $14MaintainsOutperformGet Alert
01/06/2023FATEBuy Now
Fate Therapeutics
$3.86159.07%$62 → $10MaintainsOutperformGet Alert
12/13/2022FATEBuy Now
Fate Therapeutics
$3.861506.22%$64 → $62MaintainsOutperformGet Alert
12/12/2022AFMDBuy Now
Affimed
$6.41-6.4%$100 → $60MaintainsOutperformGet Alert
11/15/2022IPHABuy Now
Innate Pharma
$2.60246.15%$10 → $9MaintainsOutperformGet Alert
11/08/2022TSVTBuy Now
2seventy bio
$3.93944.03%$42 → $41MaintainsOutperformGet Alert
11/03/2022RCUSBuy Now
Arcus Biosciences
$16.30133.13%$40 → $38MaintainsOutperformGet Alert
09/30/2022MRKBuy Now
Merck & Co
$130.93-15.99%$109 → $110MaintainsOutperformGet Alert
09/27/2022LVTXBuy Now
LAVA Therapeutics
$2.441047.54%$25 → $28MaintainsOutperformGet Alert
09/12/2022MRKBuy Now
Merck & Co
$130.93-16.75%$105 → $109MaintainsOutperformGet Alert
08/29/2022MOLNBuy Now
Molecular Partners
$4.8963.6%$30 → $8DowngradeOutperform → Market PerformGet Alert
08/11/2022BOLTBuy Now
Bolt Biotherapeutics
$0.75435.48%$8 → $4DowngradeOutperform → Market PerformGet Alert
08/04/2022RCUSBuy Now
Arcus Biosciences
$16.30200.61%$66 → $49MaintainsOutperformGet Alert
08/02/2022IPHABuy Now
Innate Pharma
$2.60284.62%$11 → $10MaintainsOutperformGet Alert
07/29/2022MRKBuy Now
Merck & Co
$130.93-19.8%$104 → $105MaintainsOutperformGet Alert
07/29/2022BNTXBuy Now
BioNTech
$97.00130.93%$223 → $224MaintainsOutperformGet Alert
07/18/2022NKTXBuy Now
Nkarta
$6.57356.62% → $30Initiates → OutperformGet Alert
07/13/2022BNTXBuy Now
BioNTech
$97.00129.9%$253 → $223UpgradeMarket Perform → OutperformGet Alert
06/24/2022FSTXBuy Now
F-star Therapeutics
$21 → $7DowngradeOutperform → Market PerformGet Alert
06/23/2022AFMDBuy Now
Affimed
$6.4140.41%$100 → $90MaintainsOutperformGet Alert
06/23/2022ACLXBuy Now
Arcellx
$54.13-29.8%$47 → $38MaintainsOutperformGet Alert

Recent Analyst Stock Rating News

The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free